Anlon Healthcare Ltd Q2 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/fhbjveijrot66llswjffmgyu.pdf

Key Takeaways


The Product Mix Shift: From API to a Broader Base

Punit Kumar Rasadia: "When we are supplying any product to any domestic customer, we are considering in mind that our raw material cost should not be more than 65% of our selling price. When we are going for the export, at that time we are keeping our raw material cost maximum 50%."

Capacity Expansion: The 700-Ton Build and the Logic Behind It

Punit Kumar Rasadia: "If we will not supply to our customer, then maybe there is a possibility that they will start to identify the new supplier. So we don't want to lose the business opportunity."

CDMO Entry and the Innovator Pipeline


Inorganic Acquisition: Diversification and De-risking

Punit Kumar Rasadia: "Basically, we want to keep the company down the line debt-free."

Competitive Moat: Chemistry, Customer Concentration, and China Plus One

Punit Kumar Rasadia: "We are selecting some molecules in which there should not be any Chinese dependency, along with there is a possibility to become the world's largest in specific molecule."

Guidance & Commitments

CommitmentSpecificsTimeline
Greenfield expansion startConstruction and commissioning to beginWithin Q3 FY26 (December 2025)
Greenfield expansion completion700-ton multipurpose plant for existing molecules16–18 months from start
CDMO commercializationThree molecules for two global innovatorsQ3 FY27
Inorganic acquisition closureFacility identified; may finalizeWithin this month or by mid of next month
EU complianceEDQM confirmation received; CEP appliedBy end of this year
USFDA audit triggerSanofi to trigger audit; DMF readyJune 2026
Debt-free targetCompany to be debt-freeLast quarter of next calendar year (Q3 next financial year)
FY27 revenue minimum₹360–400 CR, conditioned on inorganic acquisition closingFY27
FY27/FY28 revenue potential₹500–550 CR across all three facilities after commercializationFY27/FY28
Confirmed order book~₹380 CR, approximately 50% exportNext year
Blended EBITDA margin25–27% on an annual basisOngoing
Trade receivables cleanupNo dues older than 180 days in booksBy end of this financial year
Artemether and Lumefantrine revenue contributionMeaningful boost expectedLast quarter current fiscal or Q1 FY26

Key Metrics

MetricQ2 FY26
Total income₹52.32 cr, +116% YoY vs ₹24.21 cr in Q2 FY25
EBITDA₹13.77 cr, +82% YoY vs ₹7.57 cr in Q2 FY25
PAT₹9.32 cr, nearly 4x YoY vs ₹2.59 cr in Q2 FY25
Total income (H1 FY26)₹85.53 cr, +38% YoY vs ₹62.11 cr in H1 FY25
EBITDA (H1 FY26)₹20.01 cr, +38% YoY vs ₹14.55 cr in H1 FY25
PAT (H1 FY26)₹12.86 cr, doubled YoY vs ₹6.36 cr in H1 FY25
Capacity utilization84% at Rajkot facility
API share in revenue mix (H1 FY26)~70% APIs, ~27.2% intermediates
Top 5 product contribution (H1 FY26)~78% of revenue
Export share~5% direct exports; expected to close FY26 at ~30% export
FY27 export targetAt least 60% of revenue
FY26 revenue target₹180–200 cr from existing facility
FY27 revenue expectation₹360–400 cr minimum, after inorganic acquisition
Order book for FY27~₹380 cr confirmed orders, ~50% export
Blended EBITDA margin guidance25–27% on an annual basis
Debt₹4.5 cr term loan; debt-equity ratio ~0.6–0.63
Trade receivables₹107 cr, of which ~₹20–30 cr over six months old
Greenfield expansion capex₹32 cr planned; IPO proceeds reserved ₹31 cr
Inorganic acquisition size₹50–55 cr
CDMO commercialization timelineQ3 FY27 for three molecules with two innovator companies